ADVERTISEMENTS

Unit: Human Research Protections Program (HRPP), Office of Research

Applies to: Faculty and Staff involved in human research

PURPOSE:
Advertisements used to recruit subjects issued regarding research project activities will be reviewed and approved by the Medical College of Wisconsin (MCW) Institutional Review Board (IRB) as part of the initial review or via amendment.

The IRB will review the information contained in the advertisement and the mode of its communication to ensure that the documents are not coercive, unduly influential, and do not state or imply a certainty of favorable outcome or other benefits beyond what is outlined in the informed consent document and the protocol. The IRB will review the print advertisements in final format to evaluate the relative size of type used and other visual effects. When advertisements are to be taped for broadcast, the IRB will review the final audio/videotape prior to use.

DEFINITIONS:
Recruitment - seeking individuals to enroll or participate in a project

Advertising - a public announcement usually by a printed notice or voice or data broadcast that describes a project including contact information. Typically this is used for recruitment purposes for a project.

Coercion – the use of force or intimidation to persuade someone to do something which they are unwilling to do.

Undue Influence - (as a term in jurisprudence) is an equitable doctrine that involves one person taking advantage of a position of power over another person. It is where free will to bargain is not possible.

Final Format – an advertisement which has been prepared and is ready for print or to be used for recording. An advertisement which is in “final format” has:
- Identified the mode of advertisement, i.e. print flyer/poster, radio script, video script or web posting
- All text, font and style used is exactly how it will appear to potential subjects
- Incorporates all images to be used

PROCEDURE:
1. The IRB considers advertising for or soliciting subjects is the start of the informed consent process and subject selection process. Advertisements must be submitted for reviewed and approved by the IRB as part of the eBridge PRO submission for initial review. See IRB SOP: Submitting New Projects
2. When an Investigator decides after initial approval to advertise for subjects or to change the advertisement, the revised advertising should be submitted as an amendment to the ongoing project.

3. The IRB reviews the advertising to assure that it is not coercive and does not promise a certainty of cure beyond what is outlined in the consent and the protocol. This is especially critical when a project may involve subjects who are likely to be vulnerable to undue influence.

4. Investigators must obtain IRB approval for all television, radio, video or print advertisements, electronic (including email and social media) solicitations, websites, and other recruitment methods and materials intended for the recruitment of prospective subjects. All methods of advertisement require approval from the IRB prior to their use.
   a. The following examples do not qualify as an advertisement:
      - Communications intended only to be seen or heard by health professionals, such as “dear doctor” letters and doctor-to-doctor letters;
      - News stories, as long as they are not intended for recruitment purposes (e.g. including phone number at the end to contact for more information to participate in a particular project, full details of inclusion/exclusion criteria of a particular project, etc.); and
      - Publicity intended for other audiences (e.g., media releases regarding types of services available or offered by a particular clinic, institute or physician).
   Contact the MCW Office of Communications regarding the use and content of news stories and media releases.

5. When advertising is to be used, the IRB must review the information contained in the advertisement and the mode of its communication to determine that the document for recruiting subjects is not coercive and does not state or imply a certainty of favorable outcome or other benefits beyond what is outlined in the consent document and the protocol. The IRB must review the printed advertisements in final format to evaluate the relative size of type used and other visual effects. When advertisements are to be taped for broadcast, the IRB must review the final audio or video tape prior to use. After an advertisement or press release has been approved by an IRB, it must also be submitted to the MCW Office of Communications for review and approval.

The IRB can review and approve the wording of an advertisement prior to recording to avoid the necessity of rework because of inappropriate wording. The review of the recorded message prepared from IRB-approved text may be accomplished through expedited review of an amendment.

**Content of Advertisements**

1. When preparing an advertisement, social media posting or approach letter to be used to recruit potential subjects to their project, Investigators should ensure the content of the advertisement is appropriate and consistent with institutional and IRB policies.

2. Advertisements used to recruit subjects should be limited to the information the potential subjects need to determine their eligibility and interest. **When appropriately worded, the following items may be included in advertisements:**
   - The name and address of the PI or the facility where the project will be conducted
   - The purpose of the project unless otherwise justified
   - The criteria that will be used to determine eligibility for the project
• A brief summary of participation benefits, if appropriate
• Time or other commitment required of the subject
• Location of the project and the person to contact for additional information

3. Advertisements used to recruit subjects should **NOT** include the following:
   • Claims of safety, effectiveness, equivalence or superiority in reference to the drug, device or procedure under investigation.
   • Use of the terms “new” or “exciting” in reference to a drug or device without explaining that the test article is investigational.
   • Use of the term “free” in reference to treatment or procedures.
   • Use of bold or enlarged print or other means to emphasize payment or the amount to be paid.
   • Use of exculpatory language, or asking subjects to give up legal rights
   • Claims that the subject will receive therapeutic benefit from participation in the project.
   • The use of any inappropriate pictures or images that would be inconsistent with equitable subject recruitment.
   • Offers of compensation from a sponsor that would involve a coupon good for a discount on the purchase price of the product once it had been approved for marketing.
   • Exhibition of the ad in venues which are not in line with the project’s purpose or intent.

**Telephone Scripts**
1. The first contact prospective subjects make is often with an individual who follows a script to determine basic eligibility for the specific project. The IRB must review the procedures and script of talking points to assure that they adequately protect the rights and welfare of the prospective subjects. The IRB must have assurance that any information collected about prospective subjects will be appropriately handled.
2. Investigators must submit the script as part of their eBridge SmartForm submission for the IRB to review.

**Internet & Social Media Recruitment**
1. All uses of internet, and social media recruitment should be described in the eBridge SmartForm. Investigators should utilize the information under “Content for Advertisements” in this procedure with regard to acceptable wording or content.
2. Investigators who choose to post on social media must comply with all institutional policies regarding the use of social media.
3. The content of websites, social media postings and/or various internet recruitment practices must be reviewed and approved prior to posting. Exceptions to this content review are limited to the following:
   • the National Cancer Institute’s cancer clinical trial listing (PDQ),
   • the government-sponsored AIDS Clinical Trials Information Service (ACTIS), and
   • Clinicaltrials.gov, and
   • Froedtert Hospital website, Clinical Trials on the MCW/Froedtert Campus.

**Review by MCW Office of Communications**
1. After an advertisement or press release has been approved by the IRB, it must be submitted to the MCW Office of Communications for institution review and approval as to such matters as fall within the jurisdiction of the MCW Office of Communications.
REFERENCES:
21 CFR 56.107(a)
21 CFR 56.111(a)(3)
21 CFR 56.111(b)
21 CFR 50.20
21 CFR 50.25
21 CFR 812.20(b)(11)
Food and Drug Administration (FDA) Information Sheets: “Recruiting Study Subjects,”
1998 Update

SUPPORTING DOCUMENTS:
IRB SOP: Recruitment Methods and Compensation

Effective Date: 07/01/2023
Version number: 4.0
Previous Version/date: 3.0, 06/07/2013
Responsible Office: HRPP Office
Approval Date: 05/29/2023

Approved By
HRPP Authorized Official: Ryan Spellecy, PhD, Director, HRPP
Human Research Protections Program (HRPP)
Office of Research
Medical College of Wisconsin